These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34110626)

  • 1. Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States.
    Farrugia A; Bansal M; Marjanovic I
    Vox Sang; 2022 Feb; 117(2):208-219. PubMed ID: 34110626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
    Racosta JM; Sposato LA; Kimpinski K
    Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7(th) International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):139-40. PubMed ID: 25546796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.
    Stonebraker JS; Farrugia A; Gathmann B; ; Orange JS
    J Clin Immunol; 2014 Feb; 34(2):233-44. PubMed ID: 24338563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunoglobulins in PID, SID and neurological autoimmune disease].
    Borte M; Baumann U; Pittrow D; Hensel M; Fasshauer M; Huscher D; Reiser M; Stangel M; Gold R; Kirch W;
    Dtsch Med Wochenschr; 2012 Mar; 137(13):675-80. PubMed ID: 22434180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry.
    Stangel M; Baumann U; Borte M; Fasshauer M; Hensel M; Huscher D; Kirch W; Pittrow D; Reiser M; Gold R
    J Clin Immunol; 2013 Jan; 33 Suppl 1():S67-71. PubMed ID: 22976553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
    Dalakas MC
    Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of immune-mediated, dysimmune neuropathies.
    Finsterer J
    Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin use in immune deficiency and autoimmune disease states.
    Perez EE
    Am J Manag Care; 2019 Jun; 25(6 Suppl):S92-S97. PubMed ID: 31318514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.
    Lehmann HC; Hartung HP
    J Neuroimmunol; 2011 Feb; 231(1-2):61-9. PubMed ID: 21056913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin.
    Ness S
    Am J Manag Care; 2019 Jun; 25(6 Suppl):S98-S104. PubMed ID: 31318515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New indications for gamma globulins].
    Fontán G; García MC; Pascual-Salcedo D; López Trascasa M; Alvarez Doforno R; Ferreira A
    An Esp Pediatr; 1992 Jun; 36 Suppl 48():135-8. PubMed ID: 1379010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.
    Jacob S; Rajabally YA
    Curr Neuropharmacol; 2009 Dec; 7(4):337-42. PubMed ID: 20514213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of immune neuropathies.
    Van Doorn PA; Garssen MP
    Curr Opin Neurol; 2002 Oct; 15(5):623-31. PubMed ID: 12352007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review.
    Abbas A; Rajabally YA
    Curr Drug Saf; 2019; 14(1):3-13. PubMed ID: 30332974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune mediated neuropathies--an update on therapeutic strategies.
    Czaplinski A; Steck AJ
    J Neurol; 2004 Feb; 251(2):127-37. PubMed ID: 14991345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous immunoglobulin-induced eczematous eruption in autoimmune neuromuscular diseases].
    Hatake S; Shimizu F; Honda M; Takahashi S; Koga M; Kimura K; Kanda T
    Rinsho Shinkeigaku; 2022 Apr; 62(4):267-271. PubMed ID: 35354723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative.
    Farrugia A; Grazzini G; Quinti I; Candura F; Profili S; Liumbruno GM
    Blood Transfus; 2019 Nov; 17(6):449-458. PubMed ID: 31846609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results.
    Nobile-Orazio E; Terenghi F
    J Neurol; 2005 May; 252 Suppl 1():I7-13. PubMed ID: 15959669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autoimmune neuropathies: diagnosis, treatment, and recent topics].
    Ueda M; Kusunoki S
    Brain Nerve; 2011 Jun; 63(6):549-55. PubMed ID: 21613658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.